In early March 2026, India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), issued a decisive advisory cautioning against the direct and indirect promotion of obesity drugs, tightening how these drugs can be spoken about, sold, and socially understood. The move comes at a time when a new class of medications—GLP-1 receptor agonists, widely recognised through brands like Ozempic has rapidly moved beyond clinics into everyday conversation, forcing regulators to step in and redraw the boundaries between treatment and trend.
In between transformation reels or a casually dropped ‘this changed my life’ review, these drugs have slipped out of medical frameworks into culture. It is in this shift that they have begun to function as a kind of shorthand—a signal of quick, visible transformation. Public speculation around figures like Karan Johar and Adnan Sami during their weight-loss journeys, alongside Aishwarya Mohanraj’s openness about experimenting with such medications, has only deepened their visibility. The clinical has become aspirational and begun to feel normal.
What makes this shift more powerful is the convergence of visibility and vulnerability. In a country where body image is increasingly mediated by digital culture, the promise of rapid transformation naturally holds undeniable appeal. Add to that the growing awareness around GLP-1 drugs originally designed to regulate appetite and glucose levels, but now widely discussed for their weight-loss effects. The country now has the perfect storm: science meeting desire, filtered through narratives.
It is precisely this shift that India’s drug regulator has now chosen to confront. By cautioning against both direct and surrogate promotion of obesity drugs, it explicitly calls out exaggerated claims and guaranteed outcomes, while also curbing communication that undermines the role of diet and exercise. The CDSCO advisory does not ban these medications; instead, it reclaims their context. These are not lifestyle enhancers, it reminds us, but prescription treatments meant for specific clinical use.
The urgency behind this move becomes clearer when viewed against what’s coming next. With semaglutide’s patent expiry paving the way for cheaper generics, India is on the brink of a significant expansion in access to obesity drugs. As availability widens, so does the risk of misuse, not always in the form of illegal access, but in something far more insidious: misinformed demand. When people begin asking for a drug not because they need it, but because they have seen it work for someone else, the line between treatment and trend begins to blur.
For many in the communication ecosystem, this moment has been a long time coming. Neha Singh, Vice President, Enormous, observes, “Regulation in the health and wellness space was inevitable; With digital platforms becoming key drivers of health messaging, especially around weight management, the surge in influencer-driven, often unverified content, results in an oversight.” Her words capture the imbalance that had quietly taken root, where the speed of digital storytelling outpaced the responsibility of medical communication.
Singh sees this as a necessary correction, adding, “This move by regulators will catalyse a shift towards responsible, educational communication, forcing brands to adopt more authentic, science-backed messaging with increasing compliance, expert validation, and transparent communication.” In that shift lies a significant transformation: from selling outcomes to explaining processes, from aspiration to accountability.
However, in categories like obesity and weight management, the power of language has always been its flexibility. Now, that flexibility is being replaced with precision. Rishi Sen, Founder and Chief Brand Architect, The Sixth Sen, explains, “In a category like this, a claim cannot be vague, inflated, or implied through clever storytelling, it must be backed by data, supported by evidence, and anchored in credible authority.” His point underscores the central tension of this moment: storytelling may still shape perception, but it can no longer substitute proof.
Sen is also careful to resist oversimplifying the solution. The conversation, he suggests, is not about removing influencers and replacing them with doctors, but about redefining the guardrails within which both operate. “A great story is still a great story, but hard claims are not creative devices, they cannot be altered, stretched, or softened to fit a narrative in sensitive categories like obesity and weight management.” In other words, the medium is not the problem, the message is.
This becomes particularly relevant when one considers how drugs like GLP-1 injections have been framed in popular discourse. Often positioned as effortless solutions, they are stripped of the very context that makes them effective and safe. At Early.Fit, where these medications are used within structured, medically supervised programmes, there is a clear discomfort with such portrayals. Saloni Paliwal, COO & Co-Founder and Parth Chopra, CEO & Co-Founder, Early.Fit explain, “Medications are not a magic wand to treat obesity. Safe, sustainable weight care requires a holistic programme that includes medication, nutrition, and lifestyle support.” Their emphasis challenges one of the most persistent myths driving demand—the idea that these drugs can replace effort rather than support it.
And the distortion doesn’t stop at messaging with GLP-1 drugs being positioned as shortcuts through claims like ‘no gym’ or ‘no diet’, a fundamentally misleading narrative. In reality, these medications are meant to work alongside structured interventions, not replace them. The issue extends beyond messaging as well. The rise of so called ‘GLP-1 supplements’ and probiotics claiming similar effects adds confusion, while unauthorised sales through local pharmacies without proper prescriptions point to a larger systemic gap.
Manisha Kapoor, CEO & Secretary General, ASCI says, “At ASCI, we have consistently observed that healthcare remains one of the most violative sectors in our complaints reporting. ASCI’s Half Yearly Complaints Report (April to September 2025) indicates that nearly 81.6 per cent of the 332 healthcare-related cases were found to be in violation of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, reflecting the prevalence of unsubstantiated or misleading claims. Additionally, around 41 per cent of cases were not contested by advertisers as of September 2025, which points to gaps in substantiation.”
And at the centre of it all remains the consumer—caught between aspiration and information. Yash Patel, CEO & Founder, Askknatural & The Good Fats, points out, “Humans hate discomfort, so when influencers indirectly push easy fat loss drugs without clearly talking about risks, people blindly jump at the option.” He adds that surrogate promotion is commercially driven and often hides risks, pointing out that drugs like Ozempic face global lawsuits over complications, even as influencers highlight only the weight-loss benefits. His observation cuts through the complexity of policy and marketing, arriving at a simple, uncomfortable truth: demand is not always rational. It is emotional, immediate, and often shaped by what is seen rather than what is understood.
That emotional pull doesn’t just influence decisions, it reshapes expectations. “If this continues, content will slowly move from effort-driven transformation to shortcut-driven outcomes, and that can lead to long-term issues like muscle loss, dependency, and an overall decline in physical and mental health,” Patel adds, pointing to the long-term consequences of a narrative that prioritises speed over sustainability.
This is also where ASCI’s perspective becomes critical. Kapoor states, “From ASCI’s perspective, health and wellness communication must be responsible, evidence-based, and compliant with regulations. Claims should be backed by credible scientific evidence and must not imply therapeutic or disease-related benefits without substantiation.” The emphasis, then, is not just on restricting promotion, but on restoring credibility to a category where messaging has often outpaced medical context.
Seen in this light, the significance of the moment becomes clearer. The regulation is not just about what brands can or cannot say, but also about what society chooses to believe. When a drug like Ozempic becomes a shorthand for transformation, it carries assumptions that extend far beyond its clinical purpose, making the CDSCO’s intervention as much about correcting perception as about enforcing rules.
The story, however, remains in motion. As the category evolves, the focus is likely to shift towards tighter alignment between regulation, medical guidance, and marketing practices, with greater scrutiny on how obesity drugs are positioned across digital and influencer ecosystems. Going forward, brands will need to build compliance-first communication frameworks that prioritise substantiated claims and expert-led narratives. They will also need to establish clear guardrails for partnerships and adapt to a landscape where visibility alone is no longer enough to build long-term trust or as Sen puts it, “Only credibility will define the next phase.”
